Lilly to acquire Kelonia Therapeutics to advance in vivo CART cell therapies Eli Lilly and Company investorlillycom

Kelonia’s lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighte… [+7659 chars]Read More